New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
TG4050 has demonstrated the ability to induce strong immune responses against targeted antigens in patients, which are expected to result in extended remission periods.
- TG4050 has demonstrated the ability to induce strong immune responses against targeted antigens in patients, which are expected to result in extended remission periods.
- Hedi Ben Brahim, CEO of Transgene, added: "Our individualized neoantigen vaccine TG4050 continues to deliver very encouraging clinical and immune response data, combined with an excellent safety profile.
- We are continuing to build a strong and compelling clinical data set to support the benefits of this novel personalized immunotherapy.
- T-cell responses were observed for class I and class II epitopes, consisting of both de novo responses and amplifications of preexisting responses.